In order to achieve the elimination of trachoma, a country needs to demonstrate that the elimination prevalence thresholds have been achieved and then sustained for at least a two-year period. Ghana achieved the thresholds in 2008, and since 2011 has been implementing its trachoma surveillance strategy. In 2015–2016, the country conducted a district-level population-based survey (two-stage cluster random sampling methodology) to provide evidence for the validation of elimination of trachoma as a public health problem.
The surveys were conducted across 18 previously trachoma-endemic districts (evaluation units (EUs)) in the Upper West and Northern Regions of Ghana. All EUs had shown to have maintained the WHO elimination threshold for trachomatous inflammation-follicular (TF) (<5.0% prevalence) in children aged 1–9 years old. The EU TF prevalence in children aged 1–9 years old ranged from between 0.09% to 1.20%. Only one EU (Yendi 0.36%; 95% CI: 0.0–1.01) failed to meet the WHO TT elimination threshold (< 0.2% prevalence in adults aged 15 and above). The EU prevalence of trichiasis (TT) unknown to the health system in adults aged ≥15 years, ranged from 0.00% to 0.36%. The findings from this survey indicate elimination thresholds have been maintained in Ghana in 17 of the 18 surveyed EUs. Only one EU, Yendi, did not achieve the TT elimination threshold. A scheduled house-by-house TT case search in this EU coupled with surgery to clear the backlog of cases is necessary in order for Ghana to request validation of elimination of trachoma as a public health problem.
Between January and April 2016, qualitative research was conducted with those people involved in the operationalisation of the trachoma surveillance system from across all levels of the health system. This assessed both successes and challenges and highlighted that further consideration needs to be given during transition planning (from intervention to elimination) as to the adaptations to the surveillance strategy required to address contextual changes that arise as a result of transmission decline.
© 2025 by Sightsavers, Inc., Business Address for all correspondence: One Boston Place, Suite 2600, Boston, MA 02108.
To make sure you have a great experience on our site, we’d like your consent to use cookies. These will collect anonymous statistics to personalise your experience.
You have the option to enable non-essential cookies, which will help us enhance your experience and improve our website.
These enable our site to work correctly, for example by storing page settings. You can disable these by changing your browser settings, but some parts of our website will not work as expected.
To improve our website, we’d like to collect anonymous data about how you use the site, such as which pages you read, the device you’re using, and whether your visit includes a donation. This is completely anonymous, and is never used to profile individual visitors.
To raise awareness about our work, we’d like to show you Sightsavers adverts as you browse the web. By accepting these cookies, our advertising partners may use anonymous information to show you our adverts on other websites you visit. If you do not enable advertising cookies, you will still see adverts on other websites, but they may be less relevant to you. For info, see the Google Ads privacy policy.